First Time Loading...

Huaren Pharmaceutical Co Ltd
SZSE:300110

Watchlist Manager
Huaren Pharmaceutical Co Ltd Logo
Huaren Pharmaceutical Co Ltd
SZSE:300110
Watchlist
Price: 3.12 CNY -3.41% Market Closed
Updated: Jun 6, 2024
Section:
 

Relative Value

The Relative Value of one Huaren Pharmaceutical Co Ltd stock under the Base Case scenario is 5.1 CNY. Compared to the current market price of 3.12 CNY, Huaren Pharmaceutical Co Ltd is Undervalued by 39%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
5.1 CNY
Undervaluation 39%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

2.2
P/S
P/S
Price to Sales
2.2
vs History
84
vs Industry
47
Median 3Y
2.9
Median 5Y
3.1
Industry
2.4
More Details
18.6
P/E
P/E
Price to Earnings
18.6
vs History
98
vs Industry
25
Median 3Y
31.2
Median 5Y
39.8
Industry
22.4
More Details
10.6
P/OCF
P/OCF
Price to OCF
10.6
vs History
69
vs Industry
34
Median 3Y
14
Median 5Y
15.6
Industry
16.9
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
22
Median 3Y
13.7
Median 5Y
13.7
Industry
22.6
More Details
1.4
P/B
P/B
Price to Book Value
1.4
vs History
98
vs Industry
50
Median 3Y
2
Median 5Y
2.1
Industry
2
More Details
3
EV/S
EV/S
Enterprise Value to Sales
3
vs History
84
vs Industry
37
Median 3Y
3.6
Median 5Y
3.5
Industry
2.5
More Details
7.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
7.3
vs History
76
vs Industry
29
Median 3Y
9.2
Median 5Y
8.8
Industry
5.1
More Details
16.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
16.3
vs History
98
vs Industry
22
Median 3Y
25.6
Median 5Y
32.8
Industry
13.3
More Details
16.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
16.3
vs History
98
vs Industry
26
Median 3Y
25.6
Median 5Y
32.8
Industry
16.6
More Details
14.1
EV/OCF
EV/OCF
Enterprise Value to OCF
14.1
vs History
61
vs Industry
29
Median 3Y
18
Median 5Y
17.6
Industry
15.7
More Details
16.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
16.4
vs History
61
vs Industry
23
Median 3Y
21.2
Median 5Y
20.5
Industry
17.7
More Details
1
EV/IC
EV/IC
Enterprise Value to IC
1
vs History
98
vs Industry
56
Median 3Y
1.3
Median 5Y
1.4
Industry
1.9
More Details

Multiples Across Competitors

Competitors Multiples
Huaren Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Huaren Pharmaceutical Co Ltd
SZSE:300110
3.7B CNY 2.2 18.6 16.3 16.3
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
790.5B USD 22 128.8 62.9 71.6
DK
Novo Nordisk A/S
CSE:NOVO B
4.3T DKK 17.7 48.4 36.1 39.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
351.3B USD 4.1 9.1 11.3 14.7
US
Merck & Co Inc
NYSE:MRK
327.9B USD 5.3 142.2 35.4 57.8
UK
AstraZeneca PLC
LSE:AZN
195.2B GBP 5.2 39.4 175.3 279.7
CH
Roche Holding AG
SIX:ROG
190.2B CHF 3.2 16.5 9.4 11.1
CH
Novartis AG
SIX:NOVN
184.5B CHF 3.5 11.8 9 13.1
US
Pfizer Inc
NYSE:PFE
167.5B USD 3 -541.9 13 21.1
P/E Multiple
Earnings Growth
CN
Huaren Pharmaceutical Co Ltd
SZSE:300110
Average P/E: 51.9
18.6
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
128.8
364%
DK
Novo Nordisk A/S
CSE:NOVO B
48.4
83%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.1
-21%
US
Merck & Co Inc
NYSE:MRK
142.2
7 598%
UK
AstraZeneca PLC
LSE:AZN
39.4
175%
CH
Roche Holding AG
SIX:ROG
16.5
28%
CH
Novartis AG
SIX:NOVN
11.8
17%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -541.9
683%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 144,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.